GLAXO Pharmaceuticals: Major
Health Technology
Mkt Cap
118.2B
P/E (TTM)
11.24
EPS
31.48
ROE
31.52%
Div Yield
4.59%
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | ||
|---|---|---|---|---|---|---|
| Total Revenue | 65.90B | 61.19B | 49.66B | 41.84B | 36.66B | |
| Cost of Goods Sold | -42.96B | -46.73B | -46.61B | -34.92B | -27.33B | |
| Gross Profit | 22.94B | 14.46B | 3.06B | 6.92B | 9.33B | |
| SG&A Expenses | -7.06B | -6.25B | -6.32B | -4.99B | -3.72B | |
| Research & Development | -181.45M | -113.93M | -23.68M | — | — | |
| Depreciation | -1.37B | -1.14B | -932.30M | -823.38M | -775.27M | |
| Other Operating Expense | -275.51M | -139.17M | -37.11M | -31.04M | -105.84M | |
| Total Operating Expense | -50.30B | -53.12B | -52.97B | -39.94B | -31.15B | |
| Operating Income (EBIT) | 15.60B | 8.07B | -3.30B | 1.90B | 5.51B | |
| Interest Income | 518.14M | 538.91M | 277.02M | 829.54M | 374.94M | |
| Interest Expense | -116.39M | -91.66M | -63.00M | -12.74M | -7.95M | |
| Equity in Earnings | 0 | 0 | 0 | 0 | 0 | |
| Other Non-Operating Income | 745.22M | 1.98B | 5.35B | 2.59B | 1.84B | |
| Total Non-Operating Income | 1.08B | 2.41B | 5.41B | 3.21B | 1.92B | |
| Pre-Tax Income | 16.68B | 10.48B | 2.11B | 5.11B | 7.42B | |
| Income Tax | -6.66B | -3.94B | -1.57B | -2.64B | -2.07B | |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | |
| Net Income | 10.03B | 6.54B | 533.95M | 2.46B | 5.35B | |
| EBITDA | 16.97B | 9.20B | -2.37B | 2.72B | 6.28B | |
| EPS (Basic) | 31.48 | 20.52 | 1.68 | 7.73 | 16.81 | |
| EPS (Diluted) | 31.48 | 20.52 | 1.68 | 7.73 | 16.81 | |
| Gross Margin | 34.81% | 23.63% | 6.15% | 16.53% | 25.45% | |
| Operating Margin | 23.67% | 13.19% | -6.65% | 4.54% | 15.02% | |
| EBITDA Margin | 25.76% | 15.04% | -4.78% | 6.51% | 17.14% | |
| Pre-Tax Margin | 25.32% | 17.12% | 4.25% | 12.20% | 20.25% | |
| Net Margin | 15.21% | 10.68% | 1.08% | 5.89% | 14.61% |